Tanja Fehm

34.5k total citations · 5 hit papers
597 papers, 16.9k citations indexed

About

Tanja Fehm is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tanja Fehm has authored 597 papers receiving a total of 16.9k indexed citations (citations by other indexed papers that have themselves been cited), including 372 papers in Oncology, 258 papers in Cancer Research and 159 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tanja Fehm's work include Cancer Cells and Metastasis (179 papers), Breast Cancer Treatment Studies (137 papers) and Cancer Genomics and Diagnostics (125 papers). Tanja Fehm is often cited by papers focused on Cancer Cells and Metastasis (179 papers), Breast Cancer Treatment Studies (137 papers) and Cancer Genomics and Diagnostics (125 papers). Tanja Fehm collaborates with scholars based in Germany, United States and Switzerland. Tanja Fehm's co-authors include D. Wallwiener, Hans Neubauer, Sabine Kasimir‐Bauer, Wolfgang Janni, Klaus Pantel, Bahriye Aktas, Volkmar Müller, Rainer Kimmig, Erich Solomayer and Sven Becker and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Tanja Fehm

542 papers receiving 16.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

2013 928 citations Tanja Fehm, Gϋnter von Minckwitz et al. The Lancet Oncology profile →
Systemic Spread Is an Early Step in Breast Cancer

2008 903 citations Tanja Fehm et al. profile →
Circulating Tumor Cells in Patients with Breast Cancer Dormancy

2004 778 citations Leon W.M.M. Terstappen, Tanja Fehm et al. Clinical Cancer Research profile →
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients

2009 597 citations Tanja Fehm et al. Breast Cancer Research profile →
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients

2014 472 citations Brigitte Rack, Julia Jückstöck et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tanja Fehm Germany	60	10.6k	8.2k	4.3k	3.2k	1.7k	597	16.9k
Emile E. Voest Netherlands	70	8.5k 0.8×	4.9k 0.6×	7.3k 1.7×	3.1k 1.0×	1.4k 0.8×	370	18.8k
Andreas Schneeweiß Germany	61	13.3k 1.3×	8.3k 1.0×	4.6k 1.1×	4.4k 1.4×	1.6k 0.9×	608	19.1k
Sara Y. Brucker Germany	31	18.4k 1.7×	4.9k 0.6×	7.2k 1.7×	6.6k 2.1×	1.8k 1.0×	130	27.9k
Suzette Delaloge France	56	8.4k 0.8×	5.0k 0.6×	3.4k 0.8×	3.8k 1.2×	1.4k 0.8×	399	13.9k
Patrice Viens France	61	10.5k 1.0×	5.6k 0.7×	6.0k 1.4×	2.8k 0.9×	1.2k 0.7×	353	17.5k
Karen A. Gelmon Canada	73	15.9k 1.5×	7.0k 0.9×	5.6k 1.3×	6.6k 2.1×	1.9k 1.1×	393	23.8k
Hitoshi Tsuda Japan	73	7.9k 0.7×	5.7k 0.7×	7.2k 1.7×	4.2k 1.3×	3.4k 1.9×	610	20.2k
Stefan Sleijfer Netherlands	61	7.1k 0.7×	3.5k 0.4×	4.2k 1.0×	4.7k 1.5×	1.3k 0.7×	379	13.6k
Joseph A. Sparano United States	64	10.4k 1.0×	5.3k 0.6×	3.7k 0.9×	2.7k 0.9×	2.3k 1.3×	397	15.9k
Michael Craig Miller United States	45	11.5k 1.1×	8.3k 1.0×	3.5k 0.8×	5.4k 1.7×	724 0.4×	153	18.4k

Countries citing papers authored by Tanja Fehm

Since Specialization

Citations

This map shows the geographic impact of Tanja Fehm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tanja Fehm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tanja Fehm more than expected).

Fields of papers citing papers by Tanja Fehm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tanja Fehm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tanja Fehm. The network helps show where Tanja Fehm may publish in the future.

Co-authorship network of co-authors of Tanja Fehm

This figure shows the co-authorship network connecting the top 25 collaborators of Tanja Fehm. A scholar is included among the top collaborators of Tanja Fehm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tanja Fehm. Tanja Fehm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Török, J, J Dobrowolśki, Martina Helbig, et al.. (2025). Hormone and HER2-receptor status in breast cancer: determination using sonographically guided core needle biopsy and correlation with excision specimen—a German single institution diagnostic accuracy study. Archives of Gynecology and Obstetrics. 311(3). 881–891.

Fehm, Tanja, Francesco Cottone, Fabrice André, et al.. (2024). Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. The Lancet Oncology. 25(5). 614–625. 16 indexed citations

Krawczyk, Natalia, Ellen Honisch, Karl Köhrer, et al.. (2023). Whole Exome Analysis to Select Targeted Therapies for Patients with Metastatic Breast Cancer – A Feasibility Study. Geburtshilfe und Frauenheilkunde. 83(9). 1138–1147. 1 indexed citations

Banys‐Paluchowski, Maggie, Natalia Krawczyk, Elmar Stickeler, Volkmar Müller, & Tanja Fehm. (2022). New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023. Current Opinion in Obstetrics & Gynecology. 35(1). 54–61. 3 indexed citations

Liu, Hailun, et al.. (2022). Identifying Mitotic Kinesins as Potential Prognostic Biomarkers in Ovarian Cancer Using Bioinformatic Analyses. Diagnostics. 12(2). 470–470. 4 indexed citations

Krajnak, Slavomir, Thomas Decker, Christian Rosé, et al.. (2021). Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2− breast cancer resistant to endocrine therapy: VinoMetro—AGO-B-046. Journal of Cancer Research and Clinical Oncology. 147(11). 3391–3400. 6 indexed citations

Schaal, Nora K., Janine Zöllkau, Philip Hepp, Tanja Fehm, & Carsten Hagenbeck. (2021). Pregnant and breastfeeding women’s attitudes and fears regarding the COVID-19 vaccination. Archives of Gynecology and Obstetrics. 306(2). 365–372. 45 indexed citations

Schroth, Werner, Florian Büttner, Siarhei Kandabarau, et al.. (2020). Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor–Positive Breast Cancer Patients. Clinical Cancer Research. 26(24). 6523–6534. 13 indexed citations

Gierke, Berthold, Michael Pawlak, Ute Hofmann, et al.. (2020). Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression. Breast Cancer Research. 22(1). 13–13. 43 indexed citations

10.

Rensburg, Ruan van, Ellen Honisch, Martina Rudelius, et al.. (2019). EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. Molecular Cancer Research. 18(2). 278–286. 8 indexed citations

11.

Riethdorf, Sabine, Volkmar Müller, Sibylle Loibl, et al.. (2017). Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clinical Cancer Research. 23(18). 5384–5393. 82 indexed citations

12.

Laakmann, Elena, Isabell Witzel, U. Grzyska, et al.. (2016). Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry. International Journal of Molecular Sciences. 17(10). 1615–1615. 20 indexed citations

13.

Janni, Wolfgang, Brigitte Rack, Leon W.M.M. Terstappen, et al.. (2016). Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clinical Cancer Research. 22(10). 2583–2593. 265 indexed citations

14.

Mueller, Volkmar, Elena Laakmann, Tanja Fehm, et al.. (2015). Brain Metastases in Breast Cancer Network Germany (BMBC; GBG 79): Multicentric, retro- and prospective collection of patient data and biomaterial from patients with brain metastases.. Journal of Clinical Oncology. 33. 5 indexed citations

15.

Bareiss, Petra M., Anna Paczulla, Hui Wang, et al.. (2013). SOX2 Expression Associates with Stem Cell State in Human Ovarian Carcinoma. Cancer Research. 73(17). 5544–5555. 126 indexed citations

16.

Bachmann, Cornelia, et al.. (2012). CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary. Journal of Cancer Research and Clinical Oncology. 139(4). 551–556. 20 indexed citations

17.

Janni, Wolfgang, Florian D. Vogl, Gro Wiedswang, et al.. (2011). Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse—A European Pooled Analysis. Clinical Cancer Research. 17(9). 2967–2976. 192 indexed citations

18.

Riethdorf, Sabine, Volkmar Müller, Liling Zhang, et al.. (2010). Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial. Clinical Cancer Research. 16(9). 2634–2645. 398 indexed citations

19.

Fehm, Tanja, Sven Becker, Karl Sotlar, et al.. (2007). Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Research. 9(5). R74–R74. 167 indexed citations

20.

Fehm, Tanja, W. Jäger, S. Kraemer, et al.. (2005). Changes of serum HER2 status during clinical course of metastatic breast cancer patients.. PubMed. 24(6). 4205–10. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact